Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune
system called JAK3, is being developed by Pfizer to prevent transplant rejection. In study
A3921009, kidney transplant patients were given a JAK inhibitor or tacrolimus for 6 months
posttransplant. Patients who completed study A3921009 were offered the opportunity to
participate in study A3921021 which will extend the evaluation of safety and efficacy of
CP-690,550 versus tacrolimus through 8 years posttransplant. In treatment group 1 (control
arm), subjects will continue to receive tacrolimus. In treatment groups 2 and 3, subjects
will continue to receive CP-690,550. Per Amendment 4, the tacrolimus comparator arm will be
discontinued.